Compounds > bo-0742
Page last updated: 2024-11-12

bo-0742

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BO-0742: a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10458025
CHEMBL ID182739
SCHEMBL ID4910290
MeSH IDM0533841

Synonyms (10)

Synonym
[3-(acridin-9-ylamino)-5-[2-[bis(2-chloroethyl)amino]ethoxy]phenyl]methanol
CHEMBL182739
774234-08-1
unii-yq6ny3jb0c
yq6ny3jb0c ,
benzenemethanol, 3-(9-acridinylamino)-5-(2-(bis(2-chloroethyl)amino)ethoxy)-
bo-0742
SCHEMBL4910290
Q27294655
AKOS040748040
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID408353Cytotoxicity against human MX1 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID249822Average change in body weight of mice bearing human mammary carcinoma (MX-1) xenograft on 17th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID253318Average tumor size of human mammary carcinoma (MX-1) xenograft in mice on 20th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID249820Average change in body weight of mice bearing human mammary carcinoma (MX-1) xenograft on 11th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID367773Ratio of IC50 for taxol-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID248807Concentration required for growth inhibition of taxol resistant human lymphoblastic leukemic cell line (CCRF-CEM/taxol) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID408373Selectivity ratio of IC50 for vinblastine-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID248428Concentration required for growth inhibition of human HCT116 colon tumor cell line (CCRF-CEM) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID408350Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID249825Average change in body weight of mice bearing human mammary carcinoma (MX-1) xenograft on 26th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID249823Average change in body weight of mice bearing human mammary carcinoma (MX-1) xenograft on 20th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID248840Concentration required for growth inhibition of vinblastine resistant human lymphoblastic leukemic cell line (CCRF-CEM/VBL) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID367775Cytotoxicity against human MX1 cells after 72 hrs by SRB assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID266297Antiproliferative activity against human taxol resistant CCRF-CEM cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID408372Selectivity ratio of IC50 for taxol-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID408349Stability in mouse assessed as half life2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID367774Ratio of IC50 for vinblastine-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID266299Antiproliferative activity against human A549 cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID266296Antiproliferative activity against human CCRF-CEM cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID249821Average change in body weight of mice bearing human mammary carcinoma (MX-1) xenograft on 14th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID253317Average tumor size of human mammary carcinoma (MX-1) xenograft in mice on 17th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID367771Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID249824Average change in body weight of mice bearing human mammary carcinoma (MX-1) xenograft on 23th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID367776Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID367770Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID253319Average tumor size of human mammary carcinoma (MX-1) xenograft in mice on 23th day of administration (dose = 1-2 mg/kg)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID408354Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID248484Concentration required for growth inhibition of human lymphoblastic leukemic cell line (CCRF-CEM) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID248302Concentration required for growth inhibition of human lung carcinoma cell line (CCRF-CEM) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID367772Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID266298Antiproliferative activity against human vinblastine resistant CCRF-CEM cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID253320Average tumor size of human mammary carcinoma (MX-1) xenograft in mice on 26th day of administration (dose = 1-2 mg/kg); ND = Not determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID266300Antiproliferative activity against human HCT116 cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID408351Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID408352Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID266301Antiproliferative activity against human MX1 cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		2.0510acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
vinblastine
[no description available]		2.9540
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.9540taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		2.0310beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
phenylenediamine mustard
phenylenediamine mustard: RN given refers to parent cpd		2.0410
3-(9-acridinylamino)-5-hydroxymethylaniline
3-(9-acridinylamino)-5-hydroxymethylaniline: structure in first source		2.9540
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.0410L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0210
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0210
Benign Neoplasms
[description not available]		02.4520
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4520
Leucocythaemia
[description not available]		02.0510
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		07.0510